Operational Highlights Very strong quarter financially as revenues stood at ₹1452 Cr registered 33% growth YoY EBITDA stood at ₹353 Cr with EBITDA margins of 24.3% Revenues registered a strong growth on account of higher realisations per tonne for key products – Specialty Paste PVC resin, Suspension PVC, Chloromethanes and Caustic Soda. The board will …
Operational Highlights Revenue from operations in Q3FY22 at ₹4743 Cr grew by 22.5% YoY EBITDA contracted by 12.5% YoY to ₹711 Cr Revenue split Urea- 65% , P&K fertilisers- 32%, Others- 3% Urea Revenue increased due to substantial increase in gas prices during the current quarter P & K Fertilisers sales lower due to availability …
Operational Highlights Revenue grows QoQ grows by 22.4% to ₹380Cr fueled by robust demand Gross margin improves by 166 bps QoQ to 46.7% despite the inflationary trend in raw material and logistic costs EBITDA margin improves by 719 bps QoQ to 14.5% Sustained performance despite annual maintenance shut down in Diphenol Plant in Europe Revenue …
Operational Highlights The revenues for Q3FY22 stood at ₹568.4Cr from ₹373.2 Cr in same period previous year EBITDA for the quarter stood at ₹56.2Cr translating to EBITDA margins of 9.9% Revenue split for 9MFY22 Basic chemicals- 9% Dyestuff- 36% Dye intermediates- 36% Caustic soda-12% TCCA- 2% Others-5% Export revenue contributed 33% and rest 67% were …
Operational Highlights Revenues stood at ₹475 Cr in Q3FY22 compared to ₹366 Cr in Q3FY21, growth of 29.4% YoY EBITDA stood at 109.3 Cr translating 23% EBITDA margins Sales volumes were down by 13.77% from 31,993 MT in Q3FY21 to 27,589 MT in Q3FY22.as few of the clients couldn’t procure Key Starting Materials (KSMs) to …
Operational Highlights Revenue from operations for Q3FY22 grew by 53.5% YoY to ₹141.2Cr Gross margin for the 9M FY22 improved to 48.8% higher by 238 bps when compared to 9M FY21 numbers EBITDA stood at ₹30 Cr in Q3FY22 from ₹21.7 Cr in same period previous year translating a growth of 38% YoY EBITDA has …
Operational Highlights Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY Both the Pharmaceuticals and Specialty Chemicals segment outperformed during the quarter Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics …
The past 2 quarters have not been very kind to the Pharma Industry. After a post pandemic rally, the industry has been facing headwinds in FY22. The major pain points across all companies are a steep rise in prices of raw materials, energy and shipping. This has led to contraction in margins for a majority …
Net revenues for the quarter were ₹348.6 Cr (4.6% growth YoY). EBITDA for the quarter stood at ₹73.4 Cr and EBITDA margin for the quarter was 21.1%.PAT for the quarter was ₹33 Cr and PAT margins were 9.5%. Revenues from domestic formulation business for the quarter was ₹181.5 Cr (15.2% growth YoY). Major therapeutic segments …
Revenues were ₹2108 Cr (6% growth YoY), EBITDA was ₹585 Cr (5% decline YoY), PAT was ₹249 Cr (16% decline YoY). Profitability was affected due to higher than anticipated price erosion in the US market and under absorption of certain amounts of plant overheads. They have rolled out cost optimization initiatives and are confident of …